Opinion|Videos|November 4, 2024
Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications
Dr Graff discusses the differences and similarities in managing adverse events associated with bispecific antibodies in non-Hodgkin lymphoma compared to other therapeutic indications, such as multiple myeloma and non–small cell lung cancer.
Video content above is prompted by the following:
Review the recommendations on identifying, evaluating, and managing neurological toxicities.
- Workup and evaluation
- Grading of neurological toxicity
- Management of neurological toxicities
- Are there any other toxicities that are important to mention?
Please discuss the differences/similarities of bispecific antibody (BsAb) adverse event management in non-Hodgkin lymphoma vs other therapeutic indications (eg, multiple myeloma, non–small cell lung cancer).
- Is there a greater incidence of cytokine release syndrome or neurological toxicity in one disease state vs the other?
- Please address differences in BsAb protocols in different disease states.
